University of Hertfordshire

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{6cff21f0ed7040b3b8a3ffc13feb1726,
title = "Quality of Life Issues and Symptoms Reported by Patients Living with Haematological Malignancy: A Qualitative Study",
abstract = "Aim: To identify HRQoL issues and symptoms in patients with haematological malignancies (HM) and develop a conceptual framework to reflect the inter-relation between them. Methods: A total of 129 patients with HMs were interviewed in a UK multicentre qualitative study. All interviews were audio recorded, transcribed and analysed using NVivo-11. Results: Overall, 34 issues were reported by patients and were grouped into two parts: quality of life (QoL) and symptoms. The most prevalent HRQoL issues were: {\textquoteleft}eating and drinking habits; social life; physical activity; sleep; and psychological well-being{\textquoteright}. Furthermore, most prevalent disease-related symptoms were: tiredness; feeling unwell; breathlessness; lack of energy; and back pain. The most prevalent treatment side effects were: {\textquoteleft}tiredness; feeling sick; disturbance in sense of taste; and breathlessness. Conclusions: Both HMs and their treatments have a significant impact on patients{\textquoteright} HRQoL, in particular on issues such as job role change, body image and impact on finances. ",
keywords = "Haematological Malignancy, Quality of Life, Symptoms, Clinical Practice, Clinical Research",
author = "Sam Salek",
year = "2020",
month = jul,
day = "31",
language = "English",
journal = "Therapeutic Advances in Hematology",
publisher = "Sage Publications Ltd",

}

RIS

TY - JOUR

T1 - Quality of Life Issues and Symptoms Reported by Patients Living with Haematological Malignancy: A Qualitative Study

AU - Salek, Sam

PY - 2020/7/31

Y1 - 2020/7/31

N2 - Aim: To identify HRQoL issues and symptoms in patients with haematological malignancies (HM) and develop a conceptual framework to reflect the inter-relation between them. Methods: A total of 129 patients with HMs were interviewed in a UK multicentre qualitative study. All interviews were audio recorded, transcribed and analysed using NVivo-11. Results: Overall, 34 issues were reported by patients and were grouped into two parts: quality of life (QoL) and symptoms. The most prevalent HRQoL issues were: ‘eating and drinking habits; social life; physical activity; sleep; and psychological well-being’. Furthermore, most prevalent disease-related symptoms were: tiredness; feeling unwell; breathlessness; lack of energy; and back pain. The most prevalent treatment side effects were: ‘tiredness; feeling sick; disturbance in sense of taste; and breathlessness. Conclusions: Both HMs and their treatments have a significant impact on patients’ HRQoL, in particular on issues such as job role change, body image and impact on finances.

AB - Aim: To identify HRQoL issues and symptoms in patients with haematological malignancies (HM) and develop a conceptual framework to reflect the inter-relation between them. Methods: A total of 129 patients with HMs were interviewed in a UK multicentre qualitative study. All interviews were audio recorded, transcribed and analysed using NVivo-11. Results: Overall, 34 issues were reported by patients and were grouped into two parts: quality of life (QoL) and symptoms. The most prevalent HRQoL issues were: ‘eating and drinking habits; social life; physical activity; sleep; and psychological well-being’. Furthermore, most prevalent disease-related symptoms were: tiredness; feeling unwell; breathlessness; lack of energy; and back pain. The most prevalent treatment side effects were: ‘tiredness; feeling sick; disturbance in sense of taste; and breathlessness. Conclusions: Both HMs and their treatments have a significant impact on patients’ HRQoL, in particular on issues such as job role change, body image and impact on finances.

KW - Haematological Malignancy, Quality of Life, Symptoms, Clinical Practice, Clinical Research

M3 - Article

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

M1 - TAH-20-03-015.R1

ER -